ESH CLL 2022 | What physicians should know about using CARs for the treatment of CLL
In this video, Marco Ruella, MD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, shares some advice on what physicians should know regarding the use of chimeric antigen receptor T-cell (CAR-T) therapy when treating patients with chronic lymphocytic leukemia (CLL). Dr Ruella emphasizes the importance of ongoing clinical trials that are investigating the use of CAR-T products in CLL treatment, as CAR-T is not yet commercially approved for this malignancy. Dr Ruella then discusses how patients with high-risk disease or those who have relapsed should be considered for CAR-T trials, and how the management of toxicities related to CAR-T therapy have improved over the years. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
